Facebook (NASDAQ:FB): SunTrust raised Buy rated Facebook estimates to reflect expected product launches that include video ads, Instagram monetization, and graph search. The firm believes that revenues could rise 10 percent by 2017 to approximately $2 billion, and raised the price target on the shares from $40 to $55.
Anadarko (NYSE:APC): Bernstein expects Anadarko’s compound annual production growth rate to be 7 percent from 2012-2014 and the firm finds the stock valuation attractive. The firm raised its price target on the stock to $105 from $98, reiterating an Outperform rating on the shares.
Finisar (NASDAQ:FNSR): Stifel raised its price target on Finisar to $31 from $27 after the company provided stronger than expected second quarter guidance. The firm thinks that the company has several positive catalysts and reiterates a Buy rating on the stock.
MannKind (NASDAQ:MNKD): BofA/Merrill downgraded MannKind to Underperform from Neutral. The firm’s physician survey indicates an increased cautious stance following Afrezza phase three results for use in Type 2 diabetes patients on oral therapies. The firm lowered its peak share estimate to 2 percent of the oral market versus 4 percent previously. The shares’ price target has been lowered to $5 from $8.